DE3020724C2 - Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Retardwirkung - Google Patents

Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Retardwirkung

Info

Publication number
DE3020724C2
DE3020724C2 DE3020724A DE3020724A DE3020724C2 DE 3020724 C2 DE3020724 C2 DE 3020724C2 DE 3020724 A DE3020724 A DE 3020724A DE 3020724 A DE3020724 A DE 3020724A DE 3020724 C2 DE3020724 C2 DE 3020724C2
Authority
DE
Germany
Prior art keywords
cellulose
carrier
content
methocel
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3020724A
Other languages
German (de)
English (en)
Other versions
DE3020724A1 (de
Inventor
Joseph Martin Locust Valley N.Y. Schor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forest Laboratories LLC
Original Assignee
Forest Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories LLC filed Critical Forest Laboratories LLC
Publication of DE3020724A1 publication Critical patent/DE3020724A1/de
Application granted granted Critical
Publication of DE3020724C2 publication Critical patent/DE3020724C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3020724A 1979-06-14 1980-05-31 Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Retardwirkung Expired DE3020724C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/048,344 US4226849A (en) 1979-06-14 1979-06-14 Sustained release therapeutic compositions

Publications (2)

Publication Number Publication Date
DE3020724A1 DE3020724A1 (de) 1981-01-29
DE3020724C2 true DE3020724C2 (de) 1985-02-21

Family

ID=21954071

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3050558A Expired DE3050558C2 (de) 1979-06-14 1980-05-31 Trägerbasismaterial, das mit einem therapeutischen Wirkstoff kombiniert und geformt und gepreßt werden kann
DE3020724A Expired DE3020724C2 (de) 1979-06-14 1980-05-31 Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Retardwirkung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3050558A Expired DE3050558C2 (de) 1979-06-14 1980-05-31 Trägerbasismaterial, das mit einem therapeutischen Wirkstoff kombiniert und geformt und gepreßt werden kann

Country Status (17)

Country Link
US (1) US4226849A (US20030204162A1-20031030-M00001.png)
JP (1) JPS565413A (US20030204162A1-20031030-M00001.png)
AT (1) AT373147B (US20030204162A1-20031030-M00001.png)
BE (1) BE883779A (US20030204162A1-20031030-M00001.png)
CA (1) CA1141295A (US20030204162A1-20031030-M00001.png)
CH (1) CH650685A5 (US20030204162A1-20031030-M00001.png)
DE (2) DE3050558C2 (US20030204162A1-20031030-M00001.png)
ES (1) ES8104911A1 (US20030204162A1-20031030-M00001.png)
FR (1) FR2459049A1 (US20030204162A1-20031030-M00001.png)
GB (1) GB2061950B (US20030204162A1-20031030-M00001.png)
IL (1) IL58279A (US20030204162A1-20031030-M00001.png)
IT (1) IT1136186B (US20030204162A1-20031030-M00001.png)
NL (1) NL192324C (US20030204162A1-20031030-M00001.png)
PL (1) PL134410B1 (US20030204162A1-20031030-M00001.png)
SE (1) SE449179B (US20030204162A1-20031030-M00001.png)
YU (1) YU41736B (US20030204162A1-20031030-M00001.png)
ZA (1) ZA796086B (US20030204162A1-20031030-M00001.png)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4842854A (en) * 1979-05-29 1989-06-27 Vsesojuzny Kardiologichesky Nauchny Tsentr Akademii Meditsinskiki Nauk Ssr Antianginal plate for treating ischemic heart disease
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
IE49324B1 (en) * 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
NZ197543A (en) * 1980-07-02 1984-12-14 Commw Scient Ind Res Org Controlled release compositions for inclusion in intraruminal devices
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
DE3125178A1 (de) * 1981-06-26 1983-01-13 Gödecke AG, 1000 Berlin Verfahren zur zeitlichen steuerung der freisetzung von wirkstoffen aus wirkstoffzubereitungen, insbesondere arzneimittelzubereitungen
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
EP0138703B1 (en) * 1983-10-14 1989-07-26 EASTMAN KODAK COMPANY (a New Jersey corporation) Carboxylated cellulose ester
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPS61218516A (ja) * 1985-03-25 1986-09-29 Ichimaru Fuarukosu Kk 徐放性マイクロカプセルの製造法
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
DE3614095A1 (de) * 1986-04-25 1987-10-29 Goedecke Ag Oxyalkylcellulose enthaltende gelzubereitung
US4859467A (en) * 1986-09-25 1989-08-22 Colgate-Palmotive Company Sustained release fluoride composition
US4861590A (en) * 1986-09-25 1989-08-29 Colgate-Palmolive Company Sustained release fluoride and calcium composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
GB8802391D0 (en) * 1988-02-03 1988-03-02 Ddsa Pharmaceuticals Ltd Medicinal formulations
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
DE3834794A1 (de) * 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
AU652723B2 (en) * 1989-08-25 1994-09-08 Bioglan Laboratories Ltd. Pharmaceutical compositions and a device for administering the same
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
EP0465992B1 (en) * 1990-07-02 1998-06-17 Aqualon Company High solids low viscosity polysaccharide composition
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
EP1051972B1 (en) * 1994-05-27 2007-10-03 Strakan International Limited Nitric oxide donor composition and method for treatment of anal disorders
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5614207A (en) * 1995-06-30 1997-03-25 Mcneil-Ppc, Inc. Dry mouth lozenge
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20040247746A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Delivery units of thick orally soluble polymer
US20050003048A1 (en) * 2002-02-11 2005-01-06 Edizone, Lc Electrolyte-containing orally soluble films
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
CA2673334C (en) * 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
MX2009013384A (es) * 2007-06-08 2010-01-25 Addrenex Pharmaceuticals Inc Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica.
JP5336483B2 (ja) * 2007-07-05 2013-11-06 ダウ グローバル テクノロジーズ エルエルシー その場液体活性化皮膜コーティング錠およびその製法
PL2665477T3 (pl) 2011-01-20 2016-05-31 Bionevia Pharmaceuticals Inc Kompozycje epalrestatu lub jego pochodnej o zmodyfikowanym uwalnianiu i sposoby ich stosowania
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN112704668B (zh) * 2021-01-12 2022-09-30 石药集团中奇制药技术（石家庄）有限公司 一种盐酸普拉克索缓释组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2726982A (en) * 1950-05-24 1955-12-13 Irving L Ochs Hydrous gels
US3034964A (en) * 1954-03-29 1962-05-15 Vitamix Pharmaceuticals Inc Sustained action tablet containing oxytetracycline
US2949401A (en) * 1958-07-28 1960-08-16 Dome Chemicals Inc Buccal tablet containing vitamin a
US2980589A (en) * 1958-09-12 1961-04-18 American Cyanamid Co Process for producing anhydrous granulation of a medicinally active waterlabile powder
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3251824A (en) * 1961-08-22 1966-05-17 Fmc Corp Method of preparing stable aqueous dispersion-forming cellulosic aggregates
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
GB1171691A (en) 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
FR2183546B1 (US20030204162A1-20031030-M00001.png) * 1972-05-10 1975-06-20 Servier Lab
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
CA1018456A (en) 1972-06-26 1977-10-04 Hans Lowey Prolonged release lozenges
US3896108A (en) * 1974-05-10 1975-07-22 Hercules Inc Carboxyalkyl modified ethyl cellulose
US4136145A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein

Also Published As

Publication number Publication date
NL8003214A (nl) 1980-12-16
NL192324B (nl) 1997-02-03
YU146980A (en) 1983-04-30
ATA290380A (de) 1983-05-15
PL134410B1 (en) 1985-08-31
IT1136186B (it) 1986-08-27
DE3020724A1 (de) 1981-01-29
BE883779A (fr) 1980-10-01
SE8004284L (sv) 1980-12-15
PL224943A1 (US20030204162A1-20031030-M00001.png) 1981-03-13
GB2061950A (en) 1981-05-20
US4226849A (en) 1980-10-07
GB2061950B (en) 1983-03-30
ES492205A0 (es) 1981-05-16
DE3050558A1 (US20030204162A1-20031030-M00001.png) 1982-07-22
ZA796086B (en) 1980-11-26
CA1141295A (en) 1983-02-15
SE449179B (sv) 1987-04-13
NL192324C (nl) 1997-06-04
AT373147B (de) 1983-12-27
FR2459049B1 (US20030204162A1-20031030-M00001.png) 1984-03-16
CH650685A5 (it) 1985-08-15
IL58279A (en) 1982-11-30
DE3050558C2 (de) 1985-04-18
IL58279A0 (en) 1979-12-30
JPS565413A (en) 1981-01-20
YU41736B (en) 1987-12-31
ES8104911A1 (es) 1981-05-16
IT8012572A0 (it) 1980-06-13
FR2459049A1 (fr) 1981-01-09

Similar Documents

Publication Publication Date Title
DE3020724C2 (de) Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Retardwirkung
US4357469A (en) Carrier base material for prolonged release therapeutic compositions
DE69821553T2 (de) Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat
DE2332484C2 (de) Arzneimittel mit verzögerter Wirkstoffabgabe
DE3780222T2 (de) Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung.
DE3779933T2 (de) Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung.
DE69811105T2 (de) Pharmazeutische zubereitungen zur oralen verabreichung von molekulares jod
DE3437599C2 (de) Ibuprofen enthaltende Weichgelatinekapseln
DE3880762T2 (de) Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung.
DD273197A5 (de) Verfahren zur herstellung eines omeprazol enthaltenden oralen pharmazeutischen praeparates
DE60026459T2 (de) Simethicon enthaltendes Abführmittel
CH655241A5 (de) Verfahren zur herstellung therapeutisch wirksamer praeparate mit anhaltendem verlauf der wirkstoff-freisetzung.
AT409083B (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
CH640738A5 (de) Arzneimitteltablette zur peroralen applikation und verfahren zu deren herstellung.
DE3500179A1 (de) Acetylerythromycinstearat, verfahren zu dessen herstellung und dieses enthaltende arzneimittel
DE69635298T2 (de) Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
DE2710327A1 (de) Carcinostatisches mittel
US5310560A (en) Medicine for the treatment of illnesses of the respiratory organs
CH647534A5 (de) Cyclodextrin-kamillen-inklusionskomplexe, verfahren zur herstellung der komplexe und die komplexe enthaltenden praeparate.
DE69517050T2 (de) Verfahren zur stabilisation der polyungesättigten fettsäuren und verwendung dieser stabilisierten produkten in therapie und in kosmetologie
DE2718260C2 (de) Verfahren zur Herstellung einer therapeutischen Zusammensetzung
DE69433012T2 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
DE2517413A1 (de) Dermatologisch verwendbares mittel
CH654004A5 (de) Kristallmodifikationen des monohydrats und der wasserfreien form von (+)-catechin, verfahren zu deren herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.
DE69113976T2 (de) Verfahren zur galenischen herstellung eines therapeutischen mittels, insbesondere auf aspirinbasis.

Legal Events

Date Code Title Description
OD Request for examination
8172 Supplementary division/partition in:

Ref country code: DE

Ref document number: 3050558

Format of ref document f/p: P

AH Division in

Ref country code: DE

Ref document number: 3050558

Format of ref document f/p: P

Q171 Divided out to:

Ref country code: DE

Ref document number: 3050558

D2 Grant after examination
AH Division in

Ref country code: DE

Ref document number: 3050558

Format of ref document f/p: P

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: DERZEIT KEIN VERTRETER BESTELLT